Abbvie
AbbVie CEO reveals why it passed on Daiichiās cancer drug
AbbVie CEO Rich Gonzalez has revealed the company’s stance on the recent ADC transaction involving Daiichi and Merck. Despite being ...
AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...
AbbVieās Skyrizi beats J&Jās Stelara in head-to-head Crohnās disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
AbbVie acquires mitochondria biotech to boost Parkinsonās research
AbbVie has made a significant move in the field of Parkinson’s disease by acquiring Mitokinin for an upfront payment of ...
Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar
Boehringer Ingelheim, the company that recently introduced the first interchangeable biosimilar to AbbVie’s blockbuster drug Humira, is now embracing a ...
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
AbbVie drops Caribouās CRISPR-edited CAR-T therapies after failed trials
AbbVie has chosen to end its partnership with Caribou Biosciences, signaling a significant shift in its strategic focus. This decision ...
AbbVie Withdraws from CD47 Arena, Ending Partnership with I-Mab
AbbVie has officially distanced itself from I-Mab, withdrawing from a once-promising collaboration focused on the anti-CD47 antibody lemzoparlimab, leaving I-Mab ...
Biocon Biologicsā CEO reveals pricing strategy and device design for Hulio, its Humira biosimilar, in the US market
The competition in the biosimilar arena targeting AbbVie’s blockbuster drug Humira, also known as adalimumab, is heating up. However, for ...
Revance slashes Daxxifyās price to compete with AbbVieās Botox in the cosmetic market
Nashville-based company Revance had high hopes for its new cosmetic dermal filler, Daxxify, which boasted a longevity twice that of ...
BOTOX Cosmetic shows promise for neck and lower face rejuvenation in phase 3 trial
Allergan Aesthetics, a subsidiary of AbbVie, has unveiled positive top-line findings from the second out of three Phase 3 clinical ...
AbbVie drops option on Harpoonās BCMA TriTAC for multiple myeloma
AbbVie has decided against pursuing its option on Harpoon Therapeutics’ anti-BCMA T-cell engager HPN217, thus avoiding a $200 million payment ...
AbbVieās Skyrizi beats J&Jās Stelara in Crohnās disease showdown
AbbVie’s revolutionary anti-inflammatory medication, Skyrizi, has been consistently outperforming its competitors in recent clinical trials, making waves in the field ...
Takeda Ordered To Pay AbbVie $480m For Failing To Supply Lupron
AbbVie stands to potentially receive significant damages, possibly amounting to hundreds of millions of dollars, due to a contractual manufacturing ...
Aquipta Gets the Nod for Migraine Prevention in European Adults, courtesy of AbbVie
AbbVie has made a significant stride in the realm of migraine management with the European Commission’s green light for Aquipta ...
Prescription Drug Cost Concerns Escalate to Shared ‘Core Value’ Across Party Lines, Survey Finds
Mounting worries over the soaring costs of prescription drugs have transcended political boundaries to become a deeply entrenched concern among ...
Jeuveau: The gender-inclusive cosmetic injectable that rivals Botox
Evolus is revolutionizing its approach to promoting its Botox alternative. The previous campaign had been contributing to impressive growth for ...
How Skyrizi Outspent Other Drugs in a Tough Market
In July, AbbVie’s Skyrizi maintained its position as the top pharma drug ad spender for the second consecutive month, but ...
Samsung wants to describe its Humira biosimilar as “interchangeable.”
While several biosimilars of AbbVie’s top-selling drug, Humira, are already available in the US market, only one, Boehringer Ingelheim’s Cyltezo, ...
First-ever JUVĆDERM Day is announced by Allergan Aesthetics
Source – Abbvie That sounds like an exciting announcement! Allergan Aesthetics, now an AbbVie company, is celebrating the first-ever JUVĆDERM ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IVĀ IMMpulse study in ...
Expanding their strategic partnership, AbbVie and Calibr aim to advance a number of preclinical and early-stage clinical assets
Source – AbbVie On July 26, 2023, AbbVie and Calibr announced expanded strategic collaboration to advance several innovative preclinical and ...
AbbVie’s Epcoritamab (EPKINLY) Receives Positive CHMP Opinion for DLBCL Treatment
Source – AbbVieAbbVie and Genmab’s potential blockbuster drug epcoritamab has received a favorable recommendation for conditional approval in the EU ...
Epcoritamab Shows Promise in Follicular Lymphoma Trial
Source – Abbvie On 28 June 2023, AbbVie in collaboration with Genmab, disclosede the initial findings of the Phase I/II ...
AbbVie Receives Favorable CHMP Opinion for Atogepant as Preventive Treatment for Migraine in Adults
Source – AbbVie AbbVie announced on June 23, 2023, that the Committee for Medicinal Products for Human Use (CHMP) of ...
Roche’s Columvi and AbbVie’s Epkinly: The Battle for Breakthroughs in Large b Cell Lymphoma Treatment
Roche’s Columvi (glofitamab) receives FDA accelerated approval for treatment of Large b Cell Lymphoma, sparking a rivalry with AbbVie and ...
AbbVie claims that Coherus violated the Humira patent settlement by working with Mark Cuban’s pharmaceutical company
AbbVie says that Coherus breached a licensing agreement that controls the commercialization of the biosimilar in a regulatory filing. The ...
Ex-baseball player hired by AbbVie to help de-stigmatize bowel condition as part of their post-Humira growth strategy
In his second season playing professional baseball, Fowler, who won the World Series with the Chicago Cubs in 2016, had ...
In a heated dispute over blood cancer treatment, AbbVie sues BeiGene over a brand-new Imbruvica patent
AbbVie’s Pharmacyclics division claims that BeiGene’s Bruki Nsa violates a patent on its blood cancer medication Imbruvica in a recent ...
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
